A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05787587. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Study identification
- NCT ID
- NCT05787587
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 216 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 17, 2023
- Primary completion
- Sep 30, 2026
- Completion
- Apr 30, 2027
- Last update posted
- Jul 12, 2026
2023 – 2027
United States locations
- U.S. sites
- 27
- U.S. states
- 20
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Institute | Phoenix | Arizona | 85027 | — |
| The Angeles Clinic | Los Angeles | California | 90025 | — |
| Hoag Memorial Hospital | Newport Beach | California | 92663 | — |
| California Pacific Medical Center | San Francisco | California | 94115 | — |
| Sarah Cannon Research Institute | Denver | Colorado | 80218 | — |
| Yale University | New Haven | Connecticut | 06511 | — |
| Orlando Health | Orlando | Florida | 32806 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| OSF St Francis Medical Center | Peoria | Illinois | 61637 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| Dana Faber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14203 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Weil Cornell University | New York | New York | 10065 | — |
| Sarah Cannon Research Institute - Oklahoma University | Oklahoma City | Oklahoma | 73104 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Sarah Cannon Research Institute - Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| MD Anderson | Houston | Texas | 77030 | — |
| NEXT Oncology | Irving | Texas | 75039 | — |
| NEXT Oncology | San Antonio | Texas | 78229 | — |
| START Mountain Region | West Valley City | Utah | 84119 | — |
| NEXT Oncology | Fairfax | Virginia | 22031 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05787587, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 12, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05787587 live on ClinicalTrials.gov.